On November 3, new clinical data were reported for a universal CD19/CD20-targeted CAR-T cell therapy (CT1190B) in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL), demonstrating promising efficacy and manageable safety.
About the Study
CT1190B is a universal CAR-T therapy targeting CD19 and CD20, currently being evaluated in multiple investigator-initiated trials (NCT07053670, NCT06734871) for R/R NHL and related indications.
As of October 17, 2025, 14 patients were enrolled:
- 3 with follicular lymphoma (FL)
- 3 with mantle cell lymphoma (MCL)
- 8 with diffuse large B-cell lymphoma (DLBCL)
The dose-escalation phase has been completed, and the recommended lymphodepletion and cell doses have been established.
Efficacy Results
Under fludarabine 30 mg/m² ×3 + cyclophosphamide 500 mg/m² ×3:
- All 3 FL patients achieved complete response (CR).
- These included patients who had failed multiple prior therapies such as immunochemotherapy, PI3K inhibitors, autologous stem cell transplantation, CD3/CD20 bispecific antibodies, and even prior CD19 CAR-T therapy.
- CAR-T expansion peaked at 10³–10⁴ copies/μg gDNA.
Under the recommended regimen (fludarabine 30 mg/m² ×3 + cyclophosphamide 1000 mg/m² ×2):
- 8 patients were treated (2 MCL, 6 DLBCL).
- Among 6 evaluable patients, ORR was 83.3% with 4 CR (2 MCL, 2 DLBCL) and 1 PR (DLBCL).
- At the 6×10⁸ dose level, 3 of 4 evaluable patients achieved CR.
- Median Cmax at this dose reached 10⁵ copies/μg gDNA.
Safety
The main adverse events were cytokine release syndrome (CRS), cytopenia, and infections.
No cases of immune effector cell-associated neurotoxicity syndrome (ICANS), graft-versus-host disease (GVHD), or other severe toxicities were observed.
